Earlier this year, when the FDA asked Amgen to pull its rare disease drug Tavneos from the market, the California drugmaker denied the request. Now, the U.S. | The FDA has told Amgen that it is proposing to withdraw the approval of the rare disease drug Tavneos.

Biotech company Amgen (NASDAQ:AMGN) will be announcing earnings results this Thursday afternoon. Here’s what investors should know.

The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study personnel doctored the results of the drug’s pivotal study in order to make it look effective.

Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.

Amgen heads into Q1 earnings with growth from key drugs offset by pricing pressure, patent losses, and biosimilar competition.

Amgen (AMGN) is projected to report a nearly 3% fall in its Q1 earnings on April 30, after the closing bell. The consensus EPS Estimate is $4.77, while the revenue estimate is $8.57B, translating to a 5.

The Food and Drug Administration's (FDA) drug review arm has proposed withdrawing approval for Amgen Inc.’s AMGN Tavneos (avacopan), citing concerns over data integrity, lack of proven effectiveness,

The U.S. Food and Drug Administration's Center ​for Drug Evaluation ‌and Research on Monday proposed withdrawing approval of Amgen's ​drug for a ​group of rare autoimmune ⁠diseases, citing a lack ​of proven effectiveness and ​untrue statements in the application that led to its ​approval.

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

Biotech giant Amgen on April 22 announced the retirement of David Reese, executive vice president and chief technology officer, who has been with the Thousand Oaks-based company for 21 years. Reese, an M.

Statins cannot touch it. Neither can diet or exercise. Lipoprotein(a), a cholesterol-like particle hardwired into a person’s DNA, circulates at elevated levels in roughly one in five adults and raises the risk of heart attacks,